AstraZeneca logo

AZN - AstraZeneca News Story

7144p 164.0  2.3%

Last Trade - 03/04/20

Sector
Healthcare
Size
Large Cap
Market Cap £93.75bn
Enterprise Value £104.74bn
Revenue £19.89bn
Position in Universe 6th / 1834

BUZZ-Vifor Pharma: Baader cuts on gloomier prospects for potassium drug

Tue 18th February, 2020 9:31am
** Shares in Vifor Pharma  VIFN.S  drop 6% and are heading
for their worst day in 2 yrs after Baader Helvea cuts to
"reduce" from "add", citing weaker prospects for the Swiss
healthcare company's flag product Veltassa in the U.S.
    ** The drug is used to treat high levels of potassium in the
blood
    ** Britain's AstraZeneca  AZN.L  (+0.7%) reported Q4 sales
for rival drug Lokelma at $8 mln, saying it has already
surpassed Vifor's product in terms of prescriptions  urn:newsml:reuters.com:*:nL4N2AE1LR
    ** Baader cuts its peak sales estimates for the Swiss
company's drug by almost 40% to CHF 320 mln
    ** Vifor shares hit the bottom of the Swiss Mid Price Index
 .SMIM 

 ((zuzanna.szymanska@tr.com))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.